China Resources Double-Crane Pharmaceutical Co (SHSE:600062) EV-to-Revenue : 2.04 (As of May. 15, 2024)

China Resources Double-Crane Pharmaceutical Co EV-to-Revenue Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					1.19	1.11	1.20	1.75	1.65

China Resources Double-Crane Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1.63	1.60	1.57	1.65	1.83

Competitive Comparison of China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue falls into.

China Resources Double-Crane Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue for today is calculated as:

China Resources Double-Crane Pharmaceutical Co's current Enterprise Value is ¥20,950 Mil.
China Resources Double-Crane Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥10,285 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

China Resources Double-Crane Pharmaceutical Co's PS Ratiofor today is calculated as:

China Resources Double-Crane Pharmaceutical Co's share price for today is ¥23.19.
China Resources Double-Crane Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥10.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Resources Double-Crane Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Business Description